Ralf Mohrbacher

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

Detlef Schuppan, Markku Mäki, Knut E. A. Lundin et al. · New England Journal of Medicine · 2021 · 206 citations · Full text

Budesonide Is More Effective Than Mesalamine or Placebo in Short-term Treatment of Collagenous Colitis

Stephan Miehlke, Ahmed Madisch, Limas Kupčinskas et al. · Gastroenterology · 2014 · 117 citations · Full text

Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease

A Tromm, Ivan Bunganič, Eva Tomsová et al. · Gastroenterology · 2010 · 90 citations · Full text

Inflammation, Anti-inflammatory, Gastrointestinal Pharmacology +6

Clinical trial: A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis

Tilo Andus, Andreas Kocjan, Moritz Müser et al. · Inflammatory Bowel Diseases · 2010 · 64 citations

The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study

Wolfgang Kreisel, Peter Deibert, Limas Kupčinskas et al. · Digestive and Liver Disease · 2014 · 49 citations

Urology, Hepatology, Medicine +10